Enanta Pharmaceuticals | ENTA - Кредиторская задолженность





Кредиторская задолженность Изменить Дата
AbbVie USD 3.59B 28.65B 2025-12
Amgen USD 2.86B 16.65B 2026-06
Anika Therapeutics USD 6.24M 103K 2026-06
Arrowhead Research USD 27.78M 2.97M 2026-06
AstraZeneca USD 22.89B 388M 2026-06
BioCryst Pharmaceuticals USD 11.46M 501K 2026-06
Biogen USD 403.9M 45.4M 2026-06
Bristol-Myers Squibb USD 4.16B 76M 2026-06
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 7M 2026-06
Halozyme Therapeutics USD 23.61M 9.51M 2026-06
Heron Therapeutics USD 11.64M 2.67M 2026-06
Immunic USD 11.01M 873K 2026-03
Incyte USD 1.39B 1.16B 2026-06
Insmed USD 74.55M 1.18M 2026-06
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
J&J USD 9.22B 1.24B 2026-06
Karyopharm Therapeutics USD 4.28M 276K 2026-03
Ligand Pharmaceuticals USD 9.4M 27.7M 2026-06
Merck USD 3.83B 36M 2026-06
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.26B 64M 2026-06
Novavax USD 22.94M 6.84M 2026-06
Pfizer USD 4.58B 75M 2026-06
PTC Therapeutics USD 40.45M 14.96M 2026-06
Roche Holding CHF 5.54B 237M 2026-06
Sarepta Therapeutics USD 50.98M 19.39M 2026-06
Vertex Pharmaceuticals USD 3.61B 135M 2026-06